Predict your next investment

Alcresta Therapeutics company logo
HEALTHCARE | Drug Development
alcresta.com

See what CB Insights has to offer

Founded Year

2011

Stage

Series D - II | Alive

Total Raised

$95.89M

Last Raised

$10M | 2 yrs ago

About Alcresta Therapeutics

Alcresta Therapeutics operates as a specialty pharma company. The Company develops and commercializes enzyme-based products for gastrointestinal disorders, and rare diseases.

Alcresta Therapeutics Headquarter Location

One Newton Executive Park Suite 100

Newton Lower Falls, Massachusetts, 02462,

United States

617-431-3600

Latest Alcresta Therapeutics News

Relizorb Will Be Covered by Medicare

Sep 8, 2021

Copy article link The Centers for Medicare and Medicaid Services (CMS) has published a local coverage determination confirming that Relizorb — an enzyme cartridge to help in digestion for cystic fibrosis (CF) patients receiving their nutrition through enteral feeding — will be covered by Medicare. The local coverage determination (LCD) “is an important addition to the expanding medical policy gains achieved across commercial and government payers in recent years,” Jason Weiner said in a press release . Weiner is chief commercial officer at Alcresta Therapeutics , which markets Relizorb. Enteral feeding, also called tube feeding , is a method to deliver nutrients directly into the digestive tract. Relizorb is a first-of-its-kind digestive enzyme cartridge for use in enteral feeding in people with CF who have exocrine pancreatic insufficiency (EPI), or other conditions in which impaired pancreatic function leads to problems with digestion. In EPI, the thick mucus that’s characteristic of CF builds up in the pancreas and blocks the release of digestive enzymes that are needed to break down certain nutrients, most notably fats. Recommended Reading Relizorb is a cartridge that can be attached to the end of a feeding tube. The cartridge mimics the function of pancreatic fat-digesting enzymes (lipase), so that as feeding formula passes the cartridge, fat molecules are broken down into components that are easier for the body to absorb. According to Alcresta, Relizorb can break down up to 90% of fat molecules found in most enteral feeding tube formulas, including molecules that are comparatively difficult to digest but are critical for growth and development, such as certain omega-3 fatty acids. In the U.S., Relizorb is  approved for use by CF patients ages 5 and older who require supplemental nutrition. Results from an Alcresta-sponsored clinical trial called ASSURE ( NCT02750501 ) showed that Relizorb can improve the absorption of omega-3 fatty acids in tube-fed CF patients. Other  studies have shown the therapy can ease digestion-related symptoms. Results from a year-long observational study released late last year showed that using Relizorb led to significant improvements in weight and height among CF patients with EPI who require tube feeding. The CMS gave Relizorb a permanent billing code (B4105) in late 2018. With the newly issued LCD, the CMS has basically stated that Relizorb is both reasonable and necessary as a treatment for eligible patients. As such, Relizorb will be covered by Medicare, the government program that insures elderly and disabled individuals in the U.S. The new LCD “reflects the clinical benefits RELiZORB provides patients suffering from rare and acute EPI conditions like cystic fibrosis and pancreatitis [inflammation of the pancreas],” Weiner said.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Alcresta Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Alcresta Therapeutics is included in 6 Expert Collections, including Smart Money VCs (2017-2019).

S

Smart Money VCs (2017-2019)

6,297 items

We crunched the data to identify the 24 VC firms with the best combination of portfolio valuations and investment outcomes.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

R

Rare Diseases

229 items

B

Biopharmaceuticals

13,989 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,592 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

M

Medical Devices

10,769 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Alcresta Therapeutics Patents

Alcresta Therapeutics has filed 16 patents.

The 3 most popular patent topics include:

  • Nutrition
  • Fatty acids
  • Digestive system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/27/2019

6/29/2021

Fatty acids, Digestive system, Nutrition, Dietary supplements, Hepatology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/27/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/29/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Fatty acids, Digestive system, Nutrition, Dietary supplements, Hepatology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Alcresta Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Alcresta Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.